Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-06-22
2004-01-06
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S457000, C514S460000, C549S277000
Reexamination Certificate
active
06673830
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
This invention relates to antiviral compounds, in particular antiviral compounds isolated from, or derived from compounds isolated from, plants of the genus Calophyllum, specifically compounds referred to as calanolides. This invention also relates to methods of isolating antiviral compounds from Calophyllum plants, compositions comprising calanolides, related compounds, and derivatives thereof, and methods of using the compositions in clinical applications, such as antiviral therapy and the prevention of viral infection.
BACKGROUND OF THE INVENTION
Acquired immune deficiency syndrome (AIDS) is a very serious disease, reported cases of which have increased dramatically within the past several years. Estimates of reported cases in the very near future also continue to rise dramatically. Consequently, there is a great effort to develop drugs and vaccines to combat AIDS.
The AIDS virus was first identified in 1983. It has been known by several names and acronyms. It is the third known T-lymphocyte virus (HTLV-III), and it has the capacity to replicate within cells of the immune system, causing profound cell destruction. The AIDS virus is a retrovirus, a virus that uses reverse transcriptase during replication. This particular retrovirus is also known as lymphadenopathy-aissociated virus (LAV), AIDS-related virus (ARV) and, most recently, as human immunodeficiency virus (HIV). Two distinct types of HIV have been described to date, namely HIV-1 and HIV-2. The acronym HIV will be used herein to refer to HIV viruses generically.
Specifically, HIV is known to exert a profound cytopathic effect on the CD4+ helper/inducer T-cells, thereby severely compromising the immune system. HIV infection also results in neurological deterioration and, ultimately, in the death of the infected individual.
The field of viral chemotherapeutics has developed in response to the need for agents effective against retroviruses, in particular HIV. There are many ways in which an agent can exhibit: anti-retroviral activity. For example, HIV requires at least four viral proteins for replication: reverse transcriptase (RT), protease (PR), transactivator protein (TAT), and regulator of virion-protein expression (REV). Accordingly, viral replication could theoretically be inhibited through inhibition of any one or all of the proteins involved in viral replication.
Anti-retroviral agents, such as AZT and ddC, are known to inhibit RT. There also exist anti-viral agents that inhibit TAT.
Nucleoside derivatives, such as AZT, are the only clinically active agents that are currently available for antiviral therapy. Although very useful, the utility of AZT and related compounds is limited by toxicity and insufficient therapeutic indices for fully adequate therapy.
Synthetic peptides also are being developed for potential use as inhibitors of the retroviral protease in the treatment of AIDS. Although these inhibitors are effective in preventing the retroviral protease from functioning, the inhibitors suffer from some distinct disadvantages. First of all, since the active site of the protease is hindered, i.e., has reduced accessibility as compared to the remainder of the protease, the ability of the inhibitors to access and bind in the active site of the protease is impaired. Secondly, the peptide inhibitors that bind to the active site of the protease are generally poorly soluble in water, causing distinct problems in drug delivery.
Therefore, new classes of antiviral agents to be used alone or in combination with AZT and/or other agents are urgently needed for effective antiviral therapy against HIV. New agents, which may be used to prevent HIV infection, are also important.
BRIEF SUMMARY OF THE INVENTION
It is an object of the present invention to provide novel antiviral compounds, in particular antiviral compounds isolated from plants of the genus Calophyllum, specifically compounds referred to as calanolides, related compounds, and derivatives thereof.
It is another object of the present invention to provide a method of isolating novel antiviral compounds, specifically calanolides, related compounds, and derivatives thereof, from plants of the genus Calophyllum, more specifically from
Calophyllum lanigerum
Miq., var.
austrocoriaceum
(T. C. Whitmore) P. F. Stevens, from
Calophyllum teysmannii
Miq. var
inophylloide
(King) P. F. Stevens.
It is still another object of the present invention to provide a composition, in particular a pharmaceutical composition, which inhibits the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
It is an additional object of the present invention to provide a composition, in particular a pharmaceutical composition, which prevents infection of an animal, in particular a human, with a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
Yet another object of the present invention is to provide a method of treating an animal, in particular a human, infected with a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
A further object of the present invention is to provide a method of treating an animal, in particular a human, to prevent infection with a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
These and other objects of the present invention, as well as additional inventive features, will become apparent from the description herein.
The present invention provides novel antiviral compounds, in particular antiviral compounds isolated from, as well as derivatives of compounds isolated from, plants of the genus Caloplhyllum (particularly,
Calophyllum lanigerum
var.
austrocoriaceum
and
Calophyllum teysmannii
var.
inophylloide
), specifically compounds referred to as calanolides, related compounds, and derivatives thereof in substantially pure form. The present invention also provides for a method of isolating and purifying calanolides and related antiviral compounds from Calophyllum plants, in particular from
Calophyllum lanicerum
Miq., and from
Calophyllum tevsmannii
Miq. The isolated and derived compounds may be used in a composition, such as a pharmaceutical composition, which may additionally comprise one or more other antiviral agents. Such a composition has been found to inhibit the growth or replication of a virus, in particular a retrovirus, specifically a human immunodeficiency virus, such as HIV-1 or HIV-2. The composition, therefore, is expected to have utility in the therapeutic treatment of an animal, such as a human, infected with a virus, particularly a retrovirus, specifically a human immunodeficiency virus, such as HIV-1 or HIV-2, and in the prophylactic treatment of an animal, such as a human, to prevent viral infection.
REFERENCES:
patent: 5302611 (1994-04-01), Keplinger et al.
patent: 5489697 (1996-02-01), Boulanger et al.
patent: 5591770 (1997-01-01), Boyd et al.
patent: 5840921 (1998-11-01), Flavin et al.
patent: 5847164 (1998-12-01), Flavin et al.
patent: 5859049 (1999-01-01), Boyd et al.
patent: 5859050 (1999-01-01), Flavin et al.
patent: 5869324 (1999-02-01), Flavin et al.
patent: 5872264 (1999-02-01), Flavin et al.
patent: 5874591 (1999-02-01), Flavin et al.
patent: 5892060 (1999-04-01), Flavin et al.
patent: 5977385 (1999-11-01), Flavin et al.
patent: 5981770 (1999-11-01), Flavin et al.
patent: 6043271 (2000-03-01), Flavin et al.
patent: 6277879 (2001-08-01), Xu et al.
patent: 6469133 (2002-10-01), Baker et al.
patent: 6472135 (2002-10-01), Szatynski et al.
patent: 704247 (1996-04-01), None
patent: 730178 (1999-02-01), None
patent: 1 054 007 (2000-11-01), None
patent: 3043813 (2000-03-01), None
patent: WO 92/06695 (1992-04-01), None
patent: WO 94/14789 (1994-07-01), None
patent: WO 96/04263 (1996-02-01), None
patent: WO 98/38193 (1998-09-01), None
Bader et al.,Proc. Natl. Acad. Sci., 88, 6740-6744 (1991).
Bandara et al., Two Chemically Distinct Groups of Calophyllum Speci
Boyd Michael R.
Cardellina, II John H.
Cragg Gordon M.
Fuller Richard W.
Gustafson Kirk R.
Housel James
Leydig , Voit & Mayer, Ltd.
Lucas Zachariah
The United States of America as represented by the Secretary of
LandOfFree
Calanolide and related antiviral compounds, compositions,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calanolide and related antiviral compounds, compositions,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calanolide and related antiviral compounds, compositions,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3253352